Evaluation of a Nutritional Technology for Vitamin D Absorption

Evaluation of a Lipid-based Nutritional Technology for Enhancing Vitamin D Absorption in Humans

This is a prospective, 2-group crossover, randomized, double-blind study to evaluate nutrient absorption.

Inclusion Criteria:

• Adult participants (18-55 years of age)
• Body mass index (BMI) <30 kg/m2
• Males and nonpregnant, nonlactating females
• Free of gastrointestinal disorders that my impact nutrient absorption in the small intestine, endocrine, hepatic, renal, or bone diseases

Exclusion Criteria:

• Use of vitamin D or calcium supplements within 3 weeks prior to the Screening Visit.

• Use of a tanning booth/lamp within 3 weeks prior to the Screening Visit.

• Travel to sunny location within 3 weeks prior to the Screening Visit.

• Consumption of more than 3 alcoholic drinks per day starting 48 hours before the Screening Visit.

• Has an allergy or intolerance to any ingredient in the study product.

• Participating in another study that has not been approved as a concomitant study by Abbott Nutrition.

• Use of the following medications that may have interactions with vitamin D absorption or metabolism:

  • Aluminum-containing phosphate binders
  • Anticonvulsants
  • Atorvastatin
  • Calcipotriene
  • Cholestyramine
  • Cytochrome P-450 3A4 substrates
  • Digoxin
  • Diltiazem
  • Orlistat
  • Thiazide diuretics
  • Corticosteroids
  • Stimulant laxatives
  • Verapamil